Biometrix Technology. Inc. has developed theworld’s first 9G technology that arranges 9 guanine bases at regular intervalsin a molecular recognition format and DAGON technology that can detect markerproteins up to a pg/ml level. Based on this core technology, we have establisheda platform technology applicable to the detection of various genes andproteins, and based on this, we sell IVD diagnostic devices and reagents. Usingthis technology, Biometrix Technology has entered into the market forcardiovascular disease prevention and management by using cardiovascularmonitoring products to easily manage cardiovascular diseases. In addition, weare working hard to lead the field of early cancer screening moleculardiagnostics that no one has entered the market yet. Biometrix Technologycontinues to showcase the world’s leading cardiovascular and early-stage cancermolecular diagnostic reagents and hopes to become the world’s leadingprofessional healthcare company.
Autoantibodies(AAb) generated from cancerous antigens are increased in concentration by 5~10 times compared to normal in the early development stage of cancer. Using the characteristics of this AAb derived from cancer, BMT has developed a product that can screen lung cancer from Stage 1 by using the ratio of cancer antigen and AAb. Therefore, 9G testTM Cancer Screen/Lung can screen for stage 0~1 lung cancer with the highest survival rate and minimize the risk of lung cancer, monitoring the treatment process of lung cancer patients, maximizing the therapeutic effect, and testing for stage 0~1 early lung cancer is possible.